Newborn screening for severe combined immunodeficiencies (SCID) in Germany

• Published in: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz Gesundheitsforschung, Gesundheitsschutz, 2023-11, Vol.66 (11), p.1222-1231
• Main Authors: Ghosh, Sujal, Albert, Michael H, Hauck, Fabian, Hönig, Manfred, Schütz, Catharina, Schulz, Ansgar, Speckmann, Carsten
• Format: Article
• Language: ger
• ISSN: 1437-1588
• DOI: 10.1007/s00103-023-03773-6

Patients with a severe combined immunodeficiency (SCID) harbor genetic mutations disrupting T cell immunity and hence suffer severe, life-threatening infections or manifestations of immune dysregulation within the first months of their life. The only cure is to correct their immune system, usually by means of hematopoietic stem cell transplantation (HSCT). Pilot studies and national programs in the United States and in European countries have shown that patients can be identified at an early asymptomatic stage through newborn screening. This allows treatment before the occurrence of severe complications, which improves the outcome of curative strategies like HSCT.After assessment by the Federal Joint Committee (G-BA), the SCID screening was implemented into newborn screening in Germany in 2019. The first results of the screening (dry blood spot cards from around 2 million newborns between August 2019 and February 2022) were recently published. As expected, in addition to classic SCID diseases (incidence 1:54,000), infants with syndromic disorders and T cell lymphopenia were also identified. All patients with classic SCID were scheduled for curative treatment. Of the 25 patients with classic SCID, 21 were already transplanted at the time of data analysis. Only one of 21 transplanted patients died due to pre-existing infections. A comparison of the recent screening data with historical data suggests that SCID newborn screening has been successfully implemented in Germany. Patients with SCID are routinely identified very early and scheduled for curative therapy.